WO2013122160A1 - 短時間溶解型マイクロニードル - Google Patents
短時間溶解型マイクロニードル Download PDFInfo
- Publication number
- WO2013122160A1 WO2013122160A1 PCT/JP2013/053556 JP2013053556W WO2013122160A1 WO 2013122160 A1 WO2013122160 A1 WO 2013122160A1 JP 2013053556 W JP2013053556 W JP 2013053556W WO 2013122160 A1 WO2013122160 A1 WO 2013122160A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microneedle
- valuable
- mixture
- water
- soluble polymer
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/041—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
Definitions
- the present invention relates to a material for dissolving a microneedle for imparting a modification effect and / or a functional effect to the skin surface layer and / or the skin stratum corneum in a short time.
- valuables are those that are administered to the human body, such as drugs and cosmetics, and exhibit favorable effects.
- the skin stratum corneum acts as a barrier for the transmission of valuable materials, and simply applying a valuable material to the skin surface does not sufficiently penetrate the valuable material.
- a microneedle by perforating the stratum corneum using a fine needle, that is, a microneedle, it is possible to remarkably improve the transmission efficiency of valuable materials by the coating method.
- a microneedle array is a large number of microneedles integrated on a substrate.
- a microneedle patch is a product that is easy to use by adding an adhesive tape for attaching the microneedle array to the skin.
- the tape means a film, cloth or paper coated with an adhesive.
- a microneedle is made of a material that dissolves in the body and disappears through metabolism, such as a water-soluble polymer, even if the microneedle breaks and remains in the skin, no accident will occur.
- a valuable substance is contained in the water-soluble polymer, the valuable substance can be easily administered intracutaneously or subcutaneously by dissolving the inserted microneedle in the body.
- microneedles mainly composed of water-soluble polymers such as hyaluronic acid it takes 3 to 10 hours on average for microneedles mainly composed of water-soluble polymers such as hyaluronic acid to swell and dissolve in the skin, depending on the amount of moisture in the skin. For this reason, when applying the microneedle array to the facial skin, it is often applied before going to bed, and it has been difficult to apply the microneedle array to the skin at a dermatology clinic or beauty esthetic.
- the microneedles inserted into the skin are melted, and thus it is necessary to apply for a long time, and in terms of improving QOL of the patient, it is necessary to further shorten the application time.
- insulin microneedle administration to diabetic patients it may be necessary to quickly lower the blood glucose level.
- the administration of the vaccine microneedle if the application of the skin is completed in about 30 minutes, the convenience is extremely great.
- applying the microneedle array to the skin means inserting the microneedle into the skin and holding it in that state for a considerable time.
- Non-patent Document 1 Cosmetics using microneedles were first commercially produced by Cosmedy Pharmaceutical and released in October 2008. Since the microneedles required a considerable amount of time for swelling and dissolution, there was a strong demand from users to improve the microneedle dissolution rate so that it can be applied quickly.
- Some valuable materials to be included in the microneedle array are very expensive or only a small amount can be obtained.
- a microneedle array is prepared by a conventional method, the valuable material is included not only in the microneedle portion but also in the substrate portion.
- this microneedle array is inserted into the skin, valuables contained in the microneedle part are taken into the body and diffuse, but valuables present in the substrate part are discarded without being used, and expensive valuables are used. The result is low efficiency. In order to avoid loss of expensive valuables, it is only necessary to hold the valuables only at the tip of the microneedle.
- Patent Document 5 In order to hold the valuable material only at the tip of the microneedle, there is a method in which the tip of the microneedle is immersed in the valuable material aqueous solution and adhered only to the tip (Patent Document 5).
- Patent Document 5 In the conventional method in which a valuable material is simply attached to the tip, it is necessary to solve the problem that the attached portion is broken or peeled off when the microneedle is inserted into the skin, and the valuable material is not sufficiently taken in.
- the problem to be solved by the present invention is to provide a microneedle that can be dissolved quickly and absorbed quickly to solve the above-mentioned problems of the prior art. That is, the design of a microneedle patch is studied and a microneedle material that does not take time to swell and dissolve the microneedle array is provided.
- the short-time dissolution type microneedle according to the present invention which has been made to solve the above-mentioned problems, is a mixture of a water-soluble polymer and one or more saccharides selected from monosaccharides and disaccharides.
- a needle material is used.
- the dissolution time of the microneedle in the skin should be within 30 minutes. Can do.
- the amount of monosaccharide or disaccharide is less than 5% by weight, the effect of shortening the dissolution time is small. If it exceeds 40% by weight, the mechanical strength of the microneedles decreases, making it difficult to produce the microneedles and making it difficult to pierce the skin when using the microneedles.
- microneedles For the production of microneedles, a method is generally used in which a raw material aqueous solution is cast into a mold at room temperature and then taken out from the mold after drying.
- a method is generally used in which a raw material aqueous solution is cast into a mold at room temperature and then taken out from the mold after drying.
- the mechanical strength is lowered, it is difficult to remove from the mold.
- microneedles having low mechanical strength are broken during skin penetration and cannot be inserted.
- water-soluble polymers examples include synthetic polymers such as polyvinyl pyrrolidone and polyvinyl alcohol; proteins such as collagen (or hydrolyzed collagen) and gelatin; polysaccharides such as hyaluronic acid, dextrin, dextran, proteoglycan and chondroitin sulfate sodium; Suitable are carboxymethylcellulose, hydroxyethylcellulose, and the like.
- Glucose, fructose, sucrose, lactose, trehalose, and mixtures thereof can be suitably used as the monosaccharide and disaccharide mixed with the water-soluble polymer. Of these, glucose is most suitable.
- the material of the microneedle part is selected from a water-soluble polymer, a monosaccharide and a disaccharide, or
- the microneedle array substrate portion may be different as long as it is a mixture with a plurality of types of sugars.
- the microneedle may be impregnated with a valuable material such as a cosmetic raw material or a medicinal component, particularly a polymer medicinal component.
- a valuable material such as a cosmetic raw material or a medicinal component, particularly a polymer medicinal component.
- the content of valuable materials is suitably 0.001% to 20% with respect to the total weight.
- the cosmetic material include whitening ingredients such as ascorbyl palmitate, kojic acid, lucinol, tranexamic acid, oily licorice extract, vitamin A derivative, placenta extract, and adenosine sulfate Ma; retinol, retinoic acid, retinol acetate
- Anti-wrinkle components such as retinol palmitate, EGF, cell culture extract, adenosine, etc .
- blood circulation promoting components such as ⁇ -tocopherol, tocopherol acetate, capsine, vanillyl amide, etc .
- Diet components such
- high molecular medicinal component examples include bioactive peptides and derivatives thereof, nucleic acids, oligonucleotides, various antigen proteins for vaccine use, bacteria, virus fragments, and the like.
- physiologically active peptides and derivatives thereof include calcitonin, adrenocorticotropic hormone, parathyroid hormone (PTH), hPTH (1 ⁇ 34), insulin, exendin and derivatives thereof, secretin, oxytocin, angiotensin, ⁇ - Endorphins, glucagon, vasopressin, somatostatin, gastrin, luteinizing hormone releasing hormone, enkephalin, neurotensin, atrial natriuretic peptide, growth hormone, growth hormone releasing hormone, FGF, bradykinin, substance P, dynorphin, erythropoietin, thyroid stimulating hormone , Prolactin, interferon, interleukin, G-CSF, glutathione peroxidase, superoxide dismutase, desmopressin Somatomedin, endothelin, and salts thereof.
- antigen protein include influenza virus antigens, HBs surface antigens,
- microneedle array For general valuable materials, if valuable materials are dissolved in an aqueous solution of microneedle material, then the aqueous solution is cast on a mold, dried, and then removed from the mold, a microneedle array is created. A microneedle array can be created.
- the microneedle is made of a mixture of a water-soluble polymer and a saccharide (monosaccharide or disaccharide). Valuables are dissolved in a mixed aqueous solution of a water-soluble polymer and a saccharide (monosaccharide or disaccharide).
- a valuable material solution is impregnated with the tip of the microneedle, the valuable material is attached to the tip of the microneedle, and then dried to create a valuable material-attached microneedle.
- microneedle tip with the mixture of water-soluble polymer and saccharides which are microneedle materials.
- the microneedle and the valuable material are integrated, and the valuable material is completely taken into the body without peeling off the valuable material when the microneedle is inserted.
- the composition of the mixture of the water-soluble polymer and the saccharide (monosaccharide or disaccharide) used for the composition of the microneedle material and the valuable solution may or may not be the same. If they are the same, they are naturally integrated, but even if they are different types of water-soluble polymers or different types of saccharides, if they are water-soluble, the interface after drying disappears and is integrated, and valuables are not peeled off.
- the time for applying the microneedle array to the skin can be greatly shortened. If it dissolves within 30 minutes, or even within 15 minutes, the use of the microneedle becomes easier, and the use in a dermatological examination room or beauty salon becomes practical in cosmetic applications. In medical use, the administration time to the patient is shortened, and the burden on the patient is reduced.
- FIG. 1 is a cross-sectional view showing a state in which a microneedle material aqueous solution is filled in a mold having a microneedle forming recess.
- FIG. 2 is a cross-sectional view of a microneedle formed by a mold.
- FIG. 3 is a shape comparison diagram before and after application of the microneedle.
- Example 1 to 24 and Comparative Examples 1 to 13 (How to make a microneedle array)
- microneedle arrays were prepared using the microneedle materials shown in Tables 1 and 2 below.
- Tables 1 and 2 below.
- Tables 1 and 2 below.
- water-soluble polymers shown in Tables 1 and 2 are as follows.
- Hyaluronic acid is manufactured by Kikkoman Biochemifa Co., Ltd. and has a molecular weight of 800,000 (trade name: FCH-80LE).
- Dextran is purchased from Nippon Bulk Chemicals Co., Ltd. (trade name: Dextran 70).
- Polyvinylpyrrolidone is manufactured by BASF Japan ( (Product name: Kollidon 12PF), Collagen made by Nippi Co., Ltd. (trade name: Rias Shark), Seratin made by Nippi Co., Ltd. (product name: Nippi High Great Gelatin APAT), Proteoglycan made by Biomatech Japan Co., Ltd. Product name: Natural Proteoglycan).
- Monosaccharides, disaccharides, kojic acid, adenosine, retinoic acid and ⁇ -tocotopherol, sodium chondroitin sulfate, polyvinyl alcohol, carboxymethylcellulose and hydroxyethylcellulose in Tables 1 and 2 are all purchased from Wako Pure Chemical Industries, Ltd. did.
- microneedle array was prepared using the template 1 shown in FIG.
- FIG. 1 shows the mold 1 and the microneedle material aqueous solution 2 poured into the upper surface of the mold 1.
- the microneedle forming recess 11 the inlet diameter of 0.2 mm, bottom diameter of 0.04 mm, a frustoconical depth 0.8 m, are arranged in a lattice pattern on 0.6mm intervals, 1 cm 2 250 pieces are formed.
- the mold 1 is formed in a square shape having a side of 10 cm.
- FIG. 1 A cross-sectional shape of a microneedle array formed by the mold 1 is shown in FIG.
- Each microneedle has a frustoconical shape with a needle root diameter b of 0.2 mm, a tip diameter c of 0.04 mm, and a height of 0.8 mm, and is arranged in a grid at intervals of 0.6 mm. Yes.
- this microneedle array is formed in a circular shape, about 250 microneedles are included in 1 cm 2 .
- this shape of micro-idle array is referred to as 800-MN.
- This shape of microneedle is designated as 200-MN. Also in this case, about 250 microneedles are formed on 1 cm 2 on the microneedle array.
- a mixture of microneedle materials is dissolved in water to obtain a 5 to 20% solids aqueous solution.
- Kojic acid, adenosine, retinoic acid or ⁇ -tocopherol, which are valuable materials, were each dissolved in a small amount of ethanol and added to an aqueous solution of the microneedle material and mixed.
- This aqueous solution was cast at room temperature into the above-described concave portion for forming the microneedle, the moisture was evaporated and dried, and then peeled to prepare a microneedle array.
- the microneedle array was cut into a circle having a diameter of 1 cm.
- the microneedle array was lined with a sheet coated with an adhesive on one side of a circular 16 ⁇ m thick PET having a diameter of 2 cm to form a microneedle patch.
- Microneedle arrays as shown in Tables 1 and 2 were prepared for combinations of various water-soluble polymers and sugars. These microneedle arrays were applied to 4 volunteers. Applying a microneedle means inserting a microneedle and holding it in that state for a certain period of time. Application sites were 200-MN on the face and 800-MN on the upper arm. In the case of 200-MN, the microneedle array was removed after 15 minutes and the degree of dissolution of the microneedles was observed with a microscope. When dissolution was incomplete even in 1 of 4 persons after 15 minutes, a retest was performed again and the solubility after 30 minutes was observed.
- the microneedle array was removed after 30 minutes and the degree of dissolution of the microneedles was observed with a microscope. Whether it was “complete dissolution” or “incomplete dissolution” was determined by observation, and the percentage of complete dissolution among 4 persons is shown in Table 1 as an evaluation result. For example, 3/4 means that 3 out of 4 people are completely dissolved. “Complete dissolution” means that the needle shape is completely dissolved and disappeared after application to the skin, and “incomplete dissolution” means that a part of the needle shape remains.
- Table 1 shows the configuration and results of the examples
- Table 2 shows the configuration and results of the comparative examples.
- the microneedles of the present invention dissolve completely within approximately 30 minutes.
- the amount of saccharide added is expressed as a percentage by weight relative to the total weight of the water-soluble polymer + saccharide.
- K represents kojic acid
- A represents adenosine
- R represents retinoic acid
- V represents ⁇ -tocotopherol
- the addition amount is expressed in terms of% by weight relative to the total weight of the material (water-soluble polymer + saccharide).
- * indicates that a good microneedle array could not be prepared and the skin application test could not be performed.
- Fig. 3 shows a comparison of microneedle shapes before and after application.
- A is a photograph of the microneedle 200-MN before skin application.
- B is a photograph of “incomplete dissolution” after 200-MN skin application.
- C is a photograph of “complete dissolution” after 200-MN skin application.
- D is a photograph of the microneedle 800-MN before application to the skin.
- E is a photograph of “incomplete dissolution” after 800-MN skin application.
- F is a photograph in the case of “complete dissolution” after 800-MN skin application.
- Beef insulin (Nacalai Tesque Co., Ltd.) was dissolved in an aqueous hydrochloric acid solution with a pH of 2.5, and this aqueous solution was mixed with an aqueous solution containing 8% hyaluronic acid (FCH-80LE) and 2% glucose.
- FCH-80LE 8% hyaluronic acid
- a valuable material aqueous solution containing a valuable material having a concentration of (U) / ml was prepared.
- the microneedle tip portion 300 ⁇ m of the microneedle array having a needle length of 800 ⁇ m produced in the same manner as in Example 17 was immersed in an aqueous solution of valuable materials and immediately pulled up and dried.
- the content of bovine insulin per microneedle array was 0.08 units.
- this is abbreviated as bovine insulin-containing microneedle array A.
- Beef insulin (Nacalai Tesque Co., Ltd.) was dissolved in an aqueous hydrochloric acid solution having a pH of 2.5, and this aqueous solution was mixed with an aqueous solution containing 7% hydroxyethyl cellulose and 3% glucose, and 1.0 unit (U) / ml for bovine insulin.
- a valuable aqueous solution containing a valuable valuable with a concentration was prepared.
- the microneedle tip portion 250 ⁇ m of the microneedle array having a needle length of 800 ⁇ m produced in the same manner as in Example 26 was immersed in a valuable solution and immediately pulled up and dried.
- the content of bovine insulin per microneedle array was 0.07 units.
- this is abbreviated as bovine insulin-containing microneedle array B.
- Egg white albumin (Nacalai Tesque Co., Ltd.) is dissolved in a pH 7.5 phosphate buffer solution, and this aqueous solution is mixed with an aqueous solution containing 8% hyaluronic acid (FCH-80LE) and 2% trehalose (Hayashibara Co., Ltd.).
- FCH-80LE 8% hyaluronic acid
- trehalose Hayashibara Co., Ltd.
- microneedle tip portion 200 ⁇ m of a microneedle array having a needle length of 800 ⁇ m produced in the same manner as in Example 26 was immersed in a valuable solution and immediately pulled up and dried.
- the content of ovalbumin per microneedle array was 6 ⁇ g.
- this is abbreviated as ovalbumin-containing microneedle array.
- the abdomen was shaved under anesthesia using 3 Wistar male rats.
- the rat abdominal skin was transdermally administered using a spring-type administration aid.
- the microneedle array was fixed using an adhesive tape. After 30 minutes, the microneedle array was taken out and observed with a microscope. In all cases, the needle was completely dissolved in the skin.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
(マイクロニードルアレイの作成法)
実施例1~24及び比較例1~13では、下記の表1及び表2に示すマイクロニードル素材を用いてマイクロニードルアレイを作製した。なお、実施例11,12,17及び19では後述の有価物をさらに添加した。
表1及び表2に示した水溶性高分子の詳細は以下の通りである。
各種の水溶性高分子と糖類の組み合わせについて、表1、2に示すようなマイクロニードルアレイを作成した。これらのマイクロニードルアレイをボランテイア4名に適用した。マイクロニードルを適用するとは、マイクロニードルを刺入し、一定時間その状態で保持することをいう。適用部位は、200-MNは顔面に、800-MNは上腕部にした。200-MNの場合は15分後にマイクロニードルアレイを取り外してマイクロニードルの溶解程度を顕微鏡観察した。15分後4名の内1名でも溶解不完全の場合、改めて再試験を行い、30分後の溶解性を観察した。800-MNの場合は30分後にマイクロニードルアレイを取り外してマイクロニードルの溶解程度を顕微鏡観察した。観察により「完全溶解」か「不完全溶解」かを判断し、4人中完全溶解の割合人数を評価結果として表1に示した。例えば3/4は4人中3名が完全溶解したことを意味する。なお、「完全溶解」とは皮膚適用後ニードル形状が完全に溶解消失していることを、「不完全溶解」とはニードル形状が一部残存していることをいう。
牛インスリン(ナカライテスク株式会社)をpH2.5の塩酸水溶液に溶解し、この水溶液とヒアルロン酸(FCH-80LE)8%とグルコース2%を含む水溶液とを混合し、牛インスリンに関して1.0ユニット(U)/ml濃度の有価物を含む有価物水溶液を作成した。
Claims (9)
- 水溶性高分子と、単糖類及び2糖類の中から選ばれた1種若しくは複数種の糖類との混合物をマイクロニードル素材とすることを特徴とするマイクロニードル。
- マイクロニードル素材中での前記糖類の混合量が、素材総重量に対し5~40重量%である、請求項1に記載のマイクロニードル。
- マイクロニードル刺入後30分以内に溶解する、請求項1又は請求項2に記載のマイクロニードル。
- 前記糖類が、グルコース、フルクトース、シュクロース、ラクトース、トレハロース、及びこれらの混合物からなる群から選ばれた1種若しくは複数種の糖類である、請求項1ないし請求項3のいずれか1項に記載のマイクロニードル。
- 前記糖類がグルコースである、請求項4に記載のマイクロニードル。
- 前記水溶性高分子が、合成高分子、蛋白質、多糖類、若しくはそれらの混合物である、請求項1ないし請求項3のいずれか1項に記載のマイクロニードル。
- 前記水溶性高分子がポリビニルピロリドン、ポリビニルアルコール、コラーゲン、ゼラチン、ヒアルロン酸(ナトリム)、デキストリン、デキストラン、プロテオグリカン、コンドロイチン硫酸ナトリム、カルボキシメチルセルロース、ヒドロキシエチルセルロースのいずれか、もしくはそれらの混合物である、請求項6に記載のマイクロニードル。
- マイクロニードルアレイのマイクロニードル先端に有価物を付着させるに際し、有価物を水溶性高分子と単糖類や2糖類との混合物水溶液に溶解させて有価物水溶液を作成し、マイクロニードルの先端部を該有価物水溶液に浸漬し、該有価物をマイクロニードル先端に一体的に保持させる、請求項1に記載のマイクロニードル。
- 水溶性高分子と、グルコースを主とする単糖類若しくは2糖類またはその両者との混合物を素材とするマイクロニードルを用いる、マイクロニードルアレイの短時間溶解法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/372,708 US20140371713A1 (en) | 2012-02-17 | 2013-02-14 | Short-time soluble microneedle |
AU2013219321A AU2013219321B2 (en) | 2012-02-17 | 2013-02-14 | Microneedle of short-time dissolution type |
KR1020207014963A KR102281138B1 (ko) | 2012-02-17 | 2013-02-14 | 단시간 용해형 마이크로니들 |
EP13749343.3A EP2815784A4 (en) | 2012-02-17 | 2013-02-14 | MICRONADEL WITH SHORT RESOLUTION TIME |
CN201380005852.3A CN104066475B (zh) | 2012-02-17 | 2013-02-14 | 迅速溶解型微针 |
CA2864388A CA2864388C (en) | 2012-02-17 | 2013-02-14 | Short-time soluble microneedle |
KR1020147020934A KR20140125364A (ko) | 2012-02-17 | 2013-02-14 | 단시간 용해형 마이크로니들 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012048530 | 2012-02-17 | ||
JP2012-048530 | 2012-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013122160A1 true WO2013122160A1 (ja) | 2013-08-22 |
Family
ID=48984269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/053556 WO2013122160A1 (ja) | 2012-02-17 | 2013-02-14 | 短時間溶解型マイクロニードル |
Country Status (8)
Country | Link |
---|---|
US (1) | US20140371713A1 (ja) |
EP (1) | EP2815784A4 (ja) |
JP (1) | JP5472770B2 (ja) |
KR (2) | KR102281138B1 (ja) |
CN (1) | CN104066475B (ja) |
AU (1) | AU2013219321B2 (ja) |
CA (1) | CA2864388C (ja) |
WO (1) | WO2013122160A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2915557A4 (en) * | 2012-11-02 | 2016-06-15 | Cosmed Pharmaceutical Co Ltd | Retinoic acid-MICRO NEEDLE |
JP2017051312A (ja) * | 2015-09-08 | 2017-03-16 | 富士フイルム株式会社 | マイクロニードルアレイ |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102105108B (zh) | 2008-05-21 | 2013-12-04 | 谢拉杰克特股份有限公司 | 制作固体溶液穿孔器贴剂的方法及其使用 |
US20160310412A1 (en) * | 2013-12-16 | 2016-10-27 | Takeda Pharmaceutical Company Limited | Microneedle |
JPWO2015152360A1 (ja) * | 2014-04-04 | 2017-04-13 | 富士フイルム株式会社 | 不活化全粒子ワクチンを含有するマイクロニードルアレイ製剤およびその投与方法 |
US10973757B2 (en) * | 2014-10-06 | 2021-04-13 | StemProtein, LLC | Biodegardable microneedle device |
KR102497984B1 (ko) | 2015-03-19 | 2023-02-09 | 라이온 가부시키가이샤 | 마이크로 니들 제제 및 마이크로 니들 제제의 제조 방법 |
WO2016163752A1 (ko) * | 2015-04-06 | 2016-10-13 | 주식회사 엘지생활건강 | 난용성 약물 전달용 용해성 마이크로니들 |
CN114515269A (zh) * | 2015-04-06 | 2022-05-20 | 株式会社Lg生活健康 | 微针及其制造方法 |
EP3281626B1 (en) * | 2015-04-06 | 2023-08-23 | LG Household & Health Care Ltd. | Soluble microneedle for delivering poorly-soluble drug |
WO2016163753A1 (ko) * | 2015-04-06 | 2016-10-13 | 주식회사 엘지생활건강 | 단백질 또는 펩타이드 전달용 용해성 마이크로니들 |
KR102451112B1 (ko) * | 2015-04-29 | 2022-10-05 | 주식회사 엘지생활건강 | 글루타치온 함유 용해성 미세바늘 패치 |
CN106176204B (zh) * | 2015-05-08 | 2018-06-19 | 上海拓勤贸易有限公司 | 药针 |
KR102203635B1 (ko) * | 2015-06-10 | 2021-01-15 | 주식회사 엘지생활건강 | 속용해성 미세바늘 패치 |
WO2017002466A1 (ja) * | 2015-06-30 | 2017-01-05 | 日本写真印刷株式会社 | マイクロニードルシート及びその製造方法 |
CN105126242A (zh) * | 2015-07-26 | 2015-12-09 | 北京化工大学 | 一种便于抗生素皮试的高分子涂层微针贴片及其制备方法 |
KR102494543B1 (ko) | 2015-09-15 | 2023-02-02 | 주식회사 엘지생활건강 | Hpv 백신 전달용 용해성 미세바늘 패치 |
KR20170032809A (ko) | 2015-09-15 | 2017-03-23 | 주식회사 엘지생활건강 | B형 간염 치료를 위한 용해성 미세바늘 패치 |
KR102509435B1 (ko) | 2015-09-15 | 2023-03-13 | 주식회사 엘지생활건강 | 아토피 피부염 치료제 전달을 위한 용해성 미세바늘 패치 |
KR102494544B1 (ko) | 2015-09-15 | 2023-02-02 | 주식회사 엘지생활건강 | 소아마비 백신 전달용 용해성 미세바늘 패치 |
KR102486502B1 (ko) | 2015-09-15 | 2023-01-09 | 주식회사 엘지생활건강 | 여드름 치료제 전달을 위한 용해성 미세바늘 패치 |
KR102494067B1 (ko) | 2015-09-15 | 2023-01-31 | 주식회사 엘지생활건강 | 홍역 백신을 포함하는 용해성 미세바늘 패치 |
KR20170032805A (ko) | 2015-09-15 | 2017-03-23 | 주식회사 엘지생활건강 | B형 간염 예방 접종을 위한 용해성 미세바늘 패치 |
KR20170032800A (ko) | 2015-09-15 | 2017-03-23 | 주식회사 엘지생활건강 | C형 간염 치료를 위한 용해성 미세바늘 패치 |
KR102494064B1 (ko) | 2015-09-15 | 2023-01-31 | 주식회사 엘지생활건강 | 항염 효과를 가지는 용해성 미세바늘 패치 |
KR20170032806A (ko) | 2015-09-15 | 2017-03-23 | 주식회사 엘지생활건강 | 상처 치유 및 2차 감염 예방을 위한 용해성 미세바늘 패치 |
KR102494065B1 (ko) | 2015-09-15 | 2023-01-31 | 주식회사 엘지생활건강 | 항바이러스 효과를 가지는 용해성 미세바늘 패치 |
KR20170040767A (ko) | 2015-10-05 | 2017-04-13 | 주식회사 엘지생활건강 | 용해성 마이크로니들 마스크 키트 |
KR102494542B1 (ko) | 2015-10-20 | 2023-02-02 | 주식회사 엘지생활건강 | 아토피 피부염에서 가려움증 치료제를 함유한 용해성 미세바늘 패치 |
JP6634623B2 (ja) * | 2015-11-27 | 2020-01-22 | ライオン株式会社 | 溶解型マイクロニードル製剤 |
JP6970954B2 (ja) | 2016-03-16 | 2021-11-24 | コスメディ製薬株式会社 | フコイダン育毛剤 |
KR101719319B1 (ko) * | 2016-04-05 | 2017-03-23 | 주식회사 엘지생활건강 | 효율적인 피부 천공을 위한 마이크로니들 구조 |
KR101779393B1 (ko) * | 2016-07-22 | 2017-09-19 | 주식회사 파마리서치프로덕트 | 핵산을 포함하는 마이크로니들 어레이 및 이의 제조방법 |
WO2018043574A1 (ja) * | 2016-09-01 | 2018-03-08 | 久光製薬株式会社 | マイクロニードル・シート |
KR101868872B1 (ko) * | 2016-10-28 | 2018-06-19 | 권영덕 | 마이크로 니들 및 그 제조 방법 |
CN107184417B (zh) * | 2017-03-31 | 2020-04-28 | 广州新济药业科技有限公司 | 可溶性微针贴片及其制备方法 |
CN107375008B (zh) * | 2017-07-19 | 2020-07-10 | 广州新济药业科技有限公司 | 用于美白的可溶性微针贴片及其制备方法 |
EP3685876B1 (en) | 2017-09-19 | 2024-04-24 | LG Household & Health Care Ltd. | Hyaluronic acid filler using microneedle patch |
CN107569447B (zh) * | 2017-09-20 | 2021-06-18 | 广州新济薇娜生物科技有限公司 | 载有结核菌素纯蛋白衍化物的可溶性微针贴片及其制备方法 |
CN108371750B (zh) * | 2018-02-24 | 2021-06-11 | 上海揽微医疗器械有限公司 | 金属微针阵列阴模模具的制备方法 |
JP6567716B1 (ja) * | 2018-03-19 | 2019-08-28 | ナショナル・タイペイ・ユニバーシティ・オブ・テクノロジーNational Taipei University of Technology | 生分解性マイクロニードルアレイ |
US11690799B2 (en) | 2018-04-19 | 2023-07-04 | Lts Lohmann Therapie-Systeme Ag | Microneedle system for applying interferon |
KR102166065B1 (ko) * | 2018-08-06 | 2020-10-15 | 주식회사 코스칼드바이오 | 생체 용해성 마이크로니들 어레이 및 이의 제작 방법 |
CN110947085A (zh) * | 2018-09-27 | 2020-04-03 | 中科微针(北京)科技有限公司 | 一种加速聚乙烯醇可溶性微针成型和速溶给药的方法及制备的微针 |
JP2021164635A (ja) | 2020-04-03 | 2021-10-14 | コスメディ製薬株式会社 | 短時間溶解マイクロニードル |
KR102442818B1 (ko) * | 2020-09-16 | 2022-09-13 | 이승욱 | 화장품 기구 및 이를 이용한 고체상 화장품과 고체상 액체상 혼합 화장품 |
KR102414320B1 (ko) * | 2020-09-21 | 2022-06-29 | 이승욱 | 다공성 패드를 포함하는 마이크로 니들 시트 화장품 기구 |
CN114324196B (zh) * | 2020-09-29 | 2024-06-11 | 华中科技大学 | 用于增强皮肤光透明性的可溶性聚合物微针的制备及应用 |
CN112321870B (zh) * | 2020-11-06 | 2022-11-18 | 浙江工商大学 | 一种微针贴片及其制备方法和应用 |
CN112675124A (zh) * | 2020-12-29 | 2021-04-20 | 浙江摩达生物科技有限公司 | 一种改性自溶性透明质酸微针的制备方法及其在戒毒药物领域的应用 |
CN114681354A (zh) * | 2020-12-31 | 2022-07-01 | 苏州悦肤达医疗科技有限公司 | 一种微针贴片及其制备方法 |
WO2023022217A1 (ja) * | 2021-08-20 | 2023-02-23 | コスメディ製薬株式会社 | 高性能マイクロニードルアレイ |
CN114129887A (zh) * | 2021-11-19 | 2022-03-04 | 烟台魔技纳米科技有限公司 | 一种快速水溶的微针及其制备方法 |
CN114558242B (zh) * | 2022-03-04 | 2022-09-27 | 优微(珠海)生物科技有限公司 | 一种可溶性微针及其制造方法 |
CN116440058A (zh) * | 2022-10-09 | 2023-07-18 | 浙江大学 | 载胰高血糖素微针贴片 |
CN117883360A (zh) * | 2022-10-09 | 2024-04-16 | 深圳青澜生物技术有限公司 | 一种微针制剂及微针贴片的制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002517300A (ja) | 1998-06-10 | 2002-06-18 | ジョージア テック リサーチ コーポレイション | 微小針デバイスおよび製造方法ならびにそれらの使用 |
JP2003238347A (ja) | 2002-02-18 | 2003-08-27 | Nano Device & System Research Inc | 機能性マイクロパイル及びその製造方法 |
WO2008139648A1 (ja) | 2007-05-15 | 2008-11-20 | Hisamitsu Pharmaceutical Co., Inc. | マイクロニードルのコーティング方法 |
JP2009273872A (ja) | 2008-04-14 | 2009-11-26 | Kosumedei Seiyaku Kk | マイクロニードルアレイ |
JP2010029634A (ja) | 2008-07-01 | 2010-02-12 | Kosumedei Seiyaku Kk | マイクロニードルアレイ及びその製造方法 |
JP2011520550A (ja) * | 2008-05-21 | 2011-07-21 | セラジェクト, インコーポレイテッド | 固溶体穿孔器パッチの製造方法及びその使用 |
JP2011224308A (ja) * | 2010-04-21 | 2011-11-10 | Kosumedei Seiyaku Kk | マイクロニードル溶着法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS588102B2 (ja) * | 1975-09-29 | 1983-02-14 | シンニホンムセン カブシキガイシヤ | マグネトロンインキヨクノ コウゾウ |
JP2005154321A (ja) * | 2003-11-25 | 2005-06-16 | Nano Device & System Research Inc | アスコルビン酸投与用マイクロニードル |
US7361182B2 (en) | 2003-12-19 | 2008-04-22 | Lightnix, Inc. | Medical lancet |
JP2007130417A (ja) * | 2005-11-08 | 2007-05-31 | Nano Device & System Research Inc | 経皮投与装置 |
US20090182306A1 (en) * | 2006-07-21 | 2009-07-16 | Georgia Tech Research Corporation | Microneedle Devices and Methods of Drug Delivery or Fluid Withdrawal |
JPWO2008062832A1 (ja) * | 2006-11-22 | 2010-03-04 | 凸版印刷株式会社 | マイクロニードルアレイ及びマイクロニードルアレイの製造方法 |
WO2008130587A2 (en) * | 2007-04-16 | 2008-10-30 | Corium International, Inc. | Solvent-cast microneedle arrays containing active |
JP2008284318A (ja) * | 2007-05-15 | 2008-11-27 | Kosumedei Seiyaku Kk | 生体由来物質からなる投薬用微細針 |
JP5408592B2 (ja) * | 2010-03-19 | 2014-02-05 | コスメディ製薬株式会社 | マイクロニードルの迅速溶解法 |
JP2011224332A (ja) * | 2010-03-29 | 2011-11-10 | Fujifilm Corp | 経皮吸収シート及びその製造方法 |
GB201107642D0 (en) * | 2011-05-09 | 2011-06-22 | Univ Cork | Method |
-
2013
- 2013-02-14 EP EP13749343.3A patent/EP2815784A4/en not_active Ceased
- 2013-02-14 AU AU2013219321A patent/AU2013219321B2/en active Active
- 2013-02-14 WO PCT/JP2013/053556 patent/WO2013122160A1/ja active Application Filing
- 2013-02-14 CN CN201380005852.3A patent/CN104066475B/zh active Active
- 2013-02-14 US US14/372,708 patent/US20140371713A1/en not_active Abandoned
- 2013-02-14 CA CA2864388A patent/CA2864388C/en active Active
- 2013-02-14 KR KR1020207014963A patent/KR102281138B1/ko active IP Right Grant
- 2013-02-14 JP JP2013041193A patent/JP5472770B2/ja active Active
- 2013-02-14 KR KR1020147020934A patent/KR20140125364A/ko active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002517300A (ja) | 1998-06-10 | 2002-06-18 | ジョージア テック リサーチ コーポレイション | 微小針デバイスおよび製造方法ならびにそれらの使用 |
JP2003238347A (ja) | 2002-02-18 | 2003-08-27 | Nano Device & System Research Inc | 機能性マイクロパイル及びその製造方法 |
WO2008139648A1 (ja) | 2007-05-15 | 2008-11-20 | Hisamitsu Pharmaceutical Co., Inc. | マイクロニードルのコーティング方法 |
JP2009273872A (ja) | 2008-04-14 | 2009-11-26 | Kosumedei Seiyaku Kk | マイクロニードルアレイ |
JP2011520550A (ja) * | 2008-05-21 | 2011-07-21 | セラジェクト, インコーポレイテッド | 固溶体穿孔器パッチの製造方法及びその使用 |
JP2010029634A (ja) | 2008-07-01 | 2010-02-12 | Kosumedei Seiyaku Kk | マイクロニードルアレイ及びその製造方法 |
JP2011224308A (ja) * | 2010-04-21 | 2011-11-10 | Kosumedei Seiyaku Kk | マイクロニードル溶着法 |
Non-Patent Citations (1)
Title |
---|
YONSUK KA; FUMIO KAMIYAMA: "The Course of Productization of Microneedle", THE ACADEMY OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, JAPAN, vol. 69, no. 4TH, September 2009 (2009-09-01), pages 272 - 276 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2915557A4 (en) * | 2012-11-02 | 2016-06-15 | Cosmed Pharmaceutical Co Ltd | Retinoic acid-MICRO NEEDLE |
AU2013339095B2 (en) * | 2012-11-02 | 2018-01-04 | Cosmed Pharmaceutical Co., Ltd. | Retinoic acid microneedle |
JP2017051312A (ja) * | 2015-09-08 | 2017-03-16 | 富士フイルム株式会社 | マイクロニードルアレイ |
WO2017043517A1 (ja) * | 2015-09-08 | 2017-03-16 | 富士フイルム株式会社 | マイクロニードルアレイ |
Also Published As
Publication number | Publication date |
---|---|
CN104066475B (zh) | 2018-07-27 |
CA2864388C (en) | 2020-07-14 |
EP2815784A1 (en) | 2014-12-24 |
EP2815784A4 (en) | 2015-07-01 |
JP5472770B2 (ja) | 2014-04-16 |
KR20140125364A (ko) | 2014-10-28 |
US20140371713A1 (en) | 2014-12-18 |
CN104066475A (zh) | 2014-09-24 |
CA2864388A1 (en) | 2013-08-22 |
JP2013189432A (ja) | 2013-09-26 |
AU2013219321A8 (en) | 2014-10-23 |
AU2013219321A1 (en) | 2014-09-18 |
KR20200062377A (ko) | 2020-06-03 |
AU2013219321B2 (en) | 2017-07-20 |
KR102281138B1 (ko) | 2021-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5472770B2 (ja) | 短時間溶解型マイクロニードル | |
JP4427691B2 (ja) | マイクロニードルアレイ | |
JP5800799B2 (ja) | プロテオグリカンを含有するマイクロニードルアレイ | |
US8167852B2 (en) | Microneedle device and method for producing the same | |
JP4521492B2 (ja) | マイクロニードルアレイ及びその製造方法 | |
JP5472673B2 (ja) | マイクロニードルアレイ | |
JP5267910B2 (ja) | マイクロニードルアレイ | |
WO2013057819A1 (ja) | マイクロニードル溶着法 | |
JP2016512754A5 (ja) | ||
JP2009254756A (ja) | マイクロニードルアレイ | |
JP2011224308A (ja) | マイクロニードル溶着法 | |
JP6198373B2 (ja) | マイクロニードル | |
JP5778622B2 (ja) | マイクロニードル溶着法 | |
EP4389189A1 (en) | High-performance microneedle array | |
KR20240046503A (ko) | 고성능 마이크로니들 어레이 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13749343 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14372708 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013749343 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20147020934 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2864388 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2013219321 Country of ref document: AU Date of ref document: 20130214 Kind code of ref document: A |